On 23 December 2005, orphan designation (EU/3/05/343) was granted by the European Commission to Eli Lilly Nederland B.V., The Netherlands, for enzastaurin hydrochloride for the treatment of glioma.
The sponsorship was transferred to Isabelle Ramirez, Germany, in February 2016.
The sponsorship was transferred to Dlrc Pharma Services Limited, Ireland, in October 2020.
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.